Market revenue in 2023 | USD 19.6 million |
Market revenue in 2030 | USD 36.4 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Solid tumor |
Fastest growing segment | Solid Tumor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Blood Cancer, Solid Tumor |
Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Labcorp Holdings Inc, Wuxi AppTec Co Ltd, Evotec SE, Taconic Biosciences, The Jackson Laboratory |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based in-vivo cro market will help companies and investors design strategic landscapes.
Solid tumor was the largest segment with a revenue share of 47.45% in 2023. Horizon Databook has segmented the Brazil oncology based in-vivo cro market based on blood cancer, solid tumor covering the revenue growth of each sub-segment from 2018 to 2030.
With increasing potential trial of the CRO market, the Brazilian Health Ministry is making new amendments. The new regulations are expected to be an advantage for Techtrials as a functional service provider, owing to its expertise in providing services of global standards.
In December 2013, ANVISA set out a new set of guidelines for its expectations from the contractors providing outsourcing services. The guidelines are specific to manufacturing, drug control, and quality control services in the federal official gazette of Brazil.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil oncology based in-vivo cro market , including forecasts for subscribers. This country databook contains high-level insights into Brazil oncology based in-vivo cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account